US-based Corindus Vascular Robotics has secured the US Food and Drug Administration (FDA) 510(k) clearance to market its CorPath GRX robotic system.
The CorPath System has been developed to assist interventional cardiologists to perform percutaneous coronary intervention (PCI).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
During robotic-assisted PCI, physicianscan use joysticks and touchscreen controls sitting in a radiation-shielded workstation, the Interventional Cockpit, to robotically control guidewires and balloon / stent catheters during an intervention.
A component of CorPath platform, the CorPath GRX has been upgraded with features such as the Active Guide Management enabling control of the guide catheter along with robotically controlling of the guidewire and balloon or stent catheter, with one-millimeter advancement, from the control console.
This precise positioning will enable adjustment of guide catheter position during PCI procedures and can also expand the usage of CorPath for more complex cases.
CorPath GRX has also been incorporated with a redesigned bedside unit featuring an extended reach arm and a touchscreen display to streamline workflow.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCorindus chief medical officer Aaron Grantham said: "The new features of the next generation CorPath System, particularly the addition of active guide catheter management, will allow physicians to increase the complexity of procedures performed robotically.
“This is a tremendous advancement in the technology platform that will greatly extend the clinical capability of the system."
